Almirall profit rises 36.3% to 53.3 million euros through September on dermatology

Nine-month results

Almirall reported a net profit of 53.3 million euros for January to September 2026, up 36.3% on the same period a year earlier, the company said on Monday, 9 November. Its normalized net result reached 60.6 million euros, a rise that Europa Press put at 45% and El Confidencial at 46%. Gross operating result (Ebitda) climbed 22.7% to 221.7 million euros. Total income reached 893.6 million euros, up 8.2%. El Confidencial, which reports net sales separately from other income, gave a figure of 889.2 million euros, up 8.3%.

Dermatology drives growth

Dermatology sales rose 17.6% to 568.6 million euros, while the general medicine unit fell 4.7% to 320.6 million euros. Within dermatology, 520.3 million euros came from Europe, where sales grew 17.6%, according to El Confidencial. Dermatology accounts for 64% of group sales, with general medicine and over-the-counter products making up the remaining 36%.

Dermatology568.6

General medicine320.6

Dermatology

568.6 EUR million

General medicine

320.6 EUR million

Data from the article text

By region, Europe generated 814.1 million euros, or 91.5% of group sales. The United States contributed 30.9 million euros and the rest of the world 44.2 million euros.

Europe814.1

United States30.9

Rest of world44.2

Europe

814.1 EUR million

United States

30.9 EUR million

Rest of world

44.2 EUR million

Data from the article text

Reports differ on the growth of the two flagship treatments. Ilumetri, for psoriasis, rose 11.5% in Europe according to El Confidencial, while La Vanguardia reported a 20% increase to 191 million euros. Ebglyss, for atopic dermatitis, grew 75% in one report and 56% to 132 million euros in the other. Together the two products represent about a third of the business, according to La Vanguardia.

Management view

Chairman Carlos Gallardo linked the growth to the company's European dermatology business and its two treatments. He said:

“Our growth is driven by our dermatology business in Europe and the positive performance of our atopic dermatitis and psoriasis treatments.”

Almirall is controlled by the Gallardo family, according to both El Confidencial and La Vanguardia.

Costs, debt and cash

Selling costs rose 8.7% to 312.9 million euros. General and administrative spending fell 0.2% to 269.1 million euros, while research and development rose 4.6% to 107.1 million euros. That R&D figure equals 12% of net sales, in line with the company's plans, according to El Confidencial. Financial debt stood at 285 million euros. After accounting for cash, Almirall reported a net cash position of 61 million euros, which La Vanguardia said leaves room to take on leverage if a market opportunity arises.

Outlook and pipeline

For the full year, the group expects business growth of between 9% and 12% and Ebitda of between 270 and 290 million euros, according to La Vanguardia. The company is advancing six potentially disruptive development programs. Four are in proof-of-concept trials (phase II), and two more are expected to start that phase toward the end of the year. Together they target five dermatological diseases, including pyoderma gangrenosum, a rare disease that Almirall is pursuing with an anti-IL-1RAP monoclonal antibody.